Victory Capital Management Inc. Purchases 65,095 Shares of Humacyte, Inc. (NASDAQ:HUMA)

Victory Capital Management Inc. increased its position in shares of Humacyte, Inc. (NASDAQ:HUMA) by 551.6% during the 3rd quarter, Holdings Channel reports. The firm owned 76,896 shares of the company’s stock after acquiring an additional 65,095 shares during the period. Victory Capital Management Inc.’s holdings in Humacyte were worth $418,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Renaissance Technologies LLC increased its holdings in Humacyte by 693.0% in the 2nd quarter. Renaissance Technologies LLC now owns 600,300 shares of the company’s stock valued at $2,881,000 after acquiring an additional 524,600 shares during the last quarter. Virtu Financial LLC bought a new stake in Humacyte in the 1st quarter valued at $197,000. Vanguard Group Inc. increased its holdings in Humacyte by 28.7% in the 1st quarter. Vanguard Group Inc. now owns 4,019,681 shares of the company’s stock valued at $12,501,000 after acquiring an additional 896,415 shares during the last quarter. Millennium Management LLC increased its holdings in Humacyte by 504.3% in the 2nd quarter. Millennium Management LLC now owns 1,599,307 shares of the company’s stock valued at $7,677,000 after acquiring an additional 1,334,641 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its holdings in Humacyte by 62.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 254,013 shares of the company’s stock valued at $1,219,000 after acquiring an additional 97,931 shares during the last quarter. 44.71% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, CEO Laura E. Niklason sold 261,369 shares of Humacyte stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $4.40, for a total transaction of $1,150,023.60. Following the completion of the transaction, the chief executive officer now directly owns 1,730,884 shares of the company’s stock, valued at approximately $7,615,889.60. The trade was a 13.12 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Brady W. Dougan sold 427,459 shares of Humacyte stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $4.34, for a total transaction of $1,855,172.06. Following the transaction, the director now directly owns 1,992,253 shares of the company’s stock, valued at approximately $8,646,378.02. This represents a 17.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 1,662,886 shares of company stock valued at $7,489,538. Company insiders own 11.20% of the company’s stock.

Humacyte Stock Performance

Humacyte stock opened at $4.52 on Friday. Humacyte, Inc. has a twelve month low of $2.45 and a twelve month high of $9.97. The company has a quick ratio of 1.10, a current ratio of 1.10 and a debt-to-equity ratio of 0.61. The company’s 50-day moving average price is $5.22 and its 200-day moving average price is $6.16. The company has a market cap of $568.89 million, a PE ratio of -3.37 and a beta of 1.47.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the stock. Benchmark reiterated a “buy” rating and issued a $15.00 price target on shares of Humacyte in a report on Thursday, October 10th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $13.00 price target on shares of Humacyte in a report on Friday, September 20th. TD Cowen reiterated a “buy” rating and issued a $10.00 price target on shares of Humacyte in a report on Friday, October 18th. D. Boral Capital restated a “buy” rating and issued a $25.00 target price on shares of Humacyte in a report on Thursday, November 21st. Finally, HC Wainwright restated a “buy” rating and issued a $12.00 target price on shares of Humacyte in a report on Wednesday, November 13th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Buy” and an average target price of $13.00.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.